Metastatic Breast Cancer
Conditions
Keywords
Metastatic breast cancer, Circulating tumour cells, CTC, Prognostic factors, Treatment response
Brief summary
Women with metastatic breast cancer, receiving first line treatment of any kind (chemotherapy, endocrine treatment or treatment with antibodies) will be included in this trial. In connection to treatment, blood samples for determination and enumeration of circulating tumour cells will be collected at different time points. Serum and plasma will be collected and stored for future analysis of RNA and DNA.
Interventions
None listed
Sponsors
Lund University Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women with metastatic breast cancer * ECOG performance status 0-2 * Age over18 years * Signed informed concent * Predicted life expectancy over 2 months * Planned for first line systemic treatment for metastatic disease (chemotherapy, antibody treatment or endocrine treatment) * Standard imaging evaluation within 4 weeks of inclusion * Planned for standard imaging within 16 weeks after start of therapy
Exclusion criteria
* Prior medical therapy for metastatic disease (prior adjuvant chemotherapy, radiotherapy or endocrine therapy is permitted) * Inability to understand information about the study * Other malignant disease with the exception of curatively treated basal cell or squamous cell cancer of the skin and cancer in situ of the cervix
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine whether numbers of circulating tumour cells in peripheral blood can give information of prognosis, and to evaluate if the numbers of circulating tumour cells can give information of the efficacy of given treatment | Blood samples will be taken before start of treatment, at month 1, month 3, month 4 and month 6. |
Countries
Sweden
Outcome results
None listed